January 3, 2018 09:30 AM EST

Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup round for I/O work

Amber Tong

→ Celgene $CELG and its partners at bluebird bio $BLUE can add boasting rights to the FDA’s breakthrough drug program for their closely watched work …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup round for I/O work

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

ICER finds GSK inhalers offer advantages over generic competitors

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

Biohaven’s ion channel drug fails pivotal bipolar mania study

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Cel­gene and blue­bird make a 'break­through' on BC­MA-tar­get­ing CAR-T; An­oth­er can­cer drug biotech gar­ners $39M start­up round for I/O work

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup round for I/O work